Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
Background The effects of non-amplification short variant (SV) mutations in CD274 (programmed death-ligand 1 (PD-L1)) on PD-L1 protein expression and immune checkpoint inhibitors (ICPIs) therapy are unknown. Here, we present a retrospective analysis of CD274 mutations detected by comprehensive genom...
Main Authors: | Brennan Decker, Richard S.P. Huang, Karthikeyan Murugesan, Douglas A. Mata, Jeffrey S. Ross, Matthew Hiemenz, Gerald Li, James Creeden, Shakti H. Ramkissoon |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/6/e002558.full |
Similar Items
-
Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
by: Meagan Montesion, et al.
Published: (2021-05-01) -
Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome
by: Rui Han, et al.
Published: (2021-01-01) -
POS-631 TRANSITIONING OUT OF PD, WHEN AND WHY
by: I. Ayensu, et al.
Published: (2021-04-01) -
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
by: Jong Yeob Kim, et al.
Published: (2019-11-01) -
Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study
by: Julie K. Wilson, et al.
Published: (2018-04-01)